Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

1 Citeringar (Scopus)
3 Nedladdningar (Pure)

Sammanfattning

Background: Peptides radiolabeled with fluorine-18 are frequently synthesized using prosthetic groups. Among them, activated esters of 6-[ 18F]fluoronicotinic acid ([ 18F]FNA) have been prepared and successfully employed for 18F-labeling of diverse biomolecules, including peptides. The utility of [ 18F]FNA as a prosthetic compound has been demonstrated in both preclinical and clinical settings, including radiopharmaceuticals targeting prostate-specific membrane antigen and poly(ADP ribose) polymerase inhibitors. This study aims to evaluate a [ 18F]FNA-conjugated nonapeptide, [ 18F]FNA-N-CooP, for positron emission tomography imaging of intracranial BT12 glioblastoma xenografts in a mouse model. Additionally, this study highlights the importance of including control experiments with prosthetic compound alone when it constitutes a major radiometabolite. Results: [ 18F]FNA-N-CooP successfully delineated intracranial glioblastoma xenografts yielding a standardized uptake value of 0.21 ± 0.03 (n = 4) and a tumor-to-brain ratio of 1.84 ± 0.29. Ex vivo autoradiography of tumor tissue showed a partial co-localization between radioactivity uptake and the target fatty acid binding protein 3 expression. However, in vivo instability of [ 18F]FNA-N-CooP was observed, with [ 18F]FNA identified as a major radiometabolite. Notably, control studies using [ 18F]FNA alone also visualized tumors, producing a standardized uptake value of 0.90 ± 0.10 (n = 4) and a tumor-to-brain ratio of 1.51 ± 0.08. Conclusions: Both [ 18F]FNA-N-CooP and [ 18F]FNA enabled PET visualization of human glioblastoma in the mouse model. However, the prominent presence of [ 18F]FNA as radiometabolite complicates the interpretation of [ 18F]FNA-N-CooP PET data, suggesting that the observed radioactivity uptake may primarily originate from [ 18F]FNA and other radiometabolites. Enhancing peptide stability is essential for improving imaging specificity. This study underscores the critical need to assess the imaging contributions of prosthetic groups when they function as significant radiometabolites.

OriginalspråkEngelska
Artikelnummer40
Antal sidor15
TidskriftEJNMMI Radiopharmacy and Chemistry
Volym10
Nummer1
DOI
StatusPublicerad - 8 juli 2025
MoE-publikationstypA1 Tidskriftsartikel-refererad

Finansiering

We thank the research grants from the Finnish Cancer Foundation, the Finnish Cultural Foundation, the Turku University Foundation, Turku University Hospital, Sigrid Jusélius Foundation, and the Research Council of Finland (decision numbers 368560, 350117). This research was partially supported by the Research Council of Finland’s Flagship InFLAMES and ImmunoCAP projects, and the funding Decision Numbers were 337530, 357910, 352727.

FN:s SDG:er

Detta resultat bidrar till följande hållbara utvecklingsmål:

  1. SDG 3 – God hälsa och välbefinnande
    SDG 3 – God hälsa och välbefinnande

Fingeravtryck

Fördjupa i forskningsämnen för ”Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här